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Background: Infected necrotizing pancreatitis is a major burden for both the patient and the health care
system. Little is known about how hospital costs break down and how they may have shifted with the
increasing use of minimally invasive techniques. The aim of this study was to analyse inpatient hospital
costs associated with pancreatic necrosectomy.
Methods: A prospective database was used to identify all patients who underwent an intervention for
necrotizing pancreatitis. Costs of treatment were calculated using detailed information from the Decision
Support Department. Costs for open and minimally invasive surgical modalities were compared.
Results: Twelve open and 13 minimally invasive necrosectomies were performed in a cohort of 577
patients presenting over a 50-month period. One patient in each group died in hospital. Overall median
stay was 3.8 days in the intensive care unit (ICU) and 44 days on the ward. The median overall treatment
cost was US$56 674. The median largest contributors to this total were ward (26.3%), surgical personnel
(22.3%) and ICU (17.0%) costs. These did not differ statistically between the two treatment modalities.
Conclusions: Pancreatic necrosectomy uses considerable health care resources. Minimally invasive
techniques have not been shown to reduce costs. Any intervention that can reduce the length of hospital
and, in particular, ICU stay by reducing the incidence of organ failure or by preventing secondary infection
is likely to be cost-effective.
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Introduction
Acute pancreatitis has an incidence in the Western world of 40
cases per 100 000 population and would appear to be increasing.1,2
Approximately 20% of patients will develop severe disease, which,
in 30–70% of cases, will require surgical intervention.3 Such an
intervention is a life-changing event for most patients. Recent
contemporary series have shown the median hospital stay for
patients undergoing pancreatic necrosectomy is 3 months and
mortality is in the order of 7–40%.4–7 Thus, necrotizing pancre-
atitis results in a significant health burden for the individual
patient, the health care system and society as a whole.
There has been an increasing trend towards delaying surgical
intervention. In addition, several minimally invasive tech-
niques4,8,9 have been described in an effort to reduce the mortality
rates associated with this condition. Although good evidence
exists for the claim that late intervention is associated with lower
mortality,10,11 no similar evidence yet exists to guide the optimal
technique. A recent – and so far only – randomized controlled trial
(the PANTER trial) has shown that a step-up approach via drain-
age to minimally invasive surgery reduced the amount of new
onset organ failure and prevented the development of endocrine
and exocrine pancreas insufficiency at 6 months follow-up in
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comparison with the open-surgery approach.5 However, the
PANTER trial was neither designed to distinguish between
different surgical techniques, nor powered to find a difference in
mortality rates.
Previous patient series have indicated that minimally invasive
techniques require more operations and a longer hospital stay
following the intervention, yet seem to reduce the need for
intensive care unit (ICU) usage.6,12 Thus, the effect of these
techniques on overall cost is unclear. Other than the PANTER
trial, no cost analysis of minimally invasive surgery has yet
been performed and no confirmation of the trial’s finding of a
cost benefit for drainage or minimally invasive surgery5 can be
found in the literature. The aim of this study was therefore to
analyse the breakdown of the in-hospital costs associated with
pancreatic necrosectomy.
Materials and methods
Since October 2005, an evidence-based pancreatitis pathway has
been used in our institution for all patients admitted with acute
pancreatitis.13 A prospective database records demographics,
severity of illness, interventions and outcome for audit and quality
assurance purposes. All patients who underwent pancreatic
necrosectomy during the study period were subsequently identi-
fied using this database.
Our procedures for predicting the severity of pancreatitis and
developing a treatment plan are undertaken according to the
2005 UK Guidelines for the Management of Acute Pancreatitis.2
The only exception is that we use antibiotics only in the presence
of proven infection. Severe pancreatitis is defined according to
the Atlanta criteria.14 Indications for necrosectomy are defined
according to the International Association of Pancreatology
guidelines15 and include the presence of infected necrosis or
extensive necrosis in patients who have failed to progress and
remain in hospital and unwell at 4 weeks. Infected necrosis
was determined by the presence of extraluminal gas within the
necrosis (on cross-sectional imaging) or a positive culture at
fine needle aspiration (FNA). During the study period, the
frequency of FNA decreased from routine use to selective
application in patients with persistent systemic inflammatory
response syndrome (SIRS) at 2 weeks.
When intervention is indicated, the preferred approach is a
minimally invasive retroperitoneal pancreatic necrosectomy
(MIRP), as previously described.16 Open necrosectomy is per-
formed when MIRP is not possible.
Because New Zealand operates a publicly funded health system,
it is impossible to generate direct billing data for an individual.
However, fixed costs per diagnostic, intervention, treatment and
bed day consumed can be generated and thus a virtual cost per
patient can be calculated. Costs were divided into those pertaining
to personnel, investigations, treatment and ward stay, respectively.
Personnel costs include the costs of the anaesthetist and
surgeon. Both are reimbursed partly at a rate per hour or day
and partly by fixed fees. In the New Zealand system, the fixed
fees for the anaesthetist may be upgraded for higher ASA
(American Society of Anesthesiologists) levels (>3), older
patients (>70 years) and operations of longer duration (>3 h). In
addition, hospital ICU patients who require ventilation for a
procedure performed outside the ICU (radiology or gastroenter-
ology) will be accompanied by the anaesthetist, for which a fixed
fee applies. Surgical personnel costs include the costs of the
consultant, registrars and house officers, both on the surgical
ward and in theatre. Miscellaneous personnel costs include the
costs of consultations in other departments and costs of person-
nel such as diabetes nurses, occupational therapists, speech and
language therapists and social workers. The hours worked by
each of these groups could not be isolated and therefore total
costs were used.
Given the great heterogeneity in the costs of different tests or
materials for endoscopy, nutrition, pathology, microbiology,
chemistry, haematology and radiology, only the number of tests
and total costs per patient were retrieved. Radiology tests were
divided into interventional and diagnostic computed tomography
(CT) and ‘other’.
Endoscopic procedures are performed by both gastroenterolo-
gists and surgeons in the gastroenterology department or the
operating theatre. The extra personnel-related costs of surgeons
performing endoscopic procedures were included under endos-
copy costs. Endoscopies performed in theatre were reimbursed
under theatre costs.
Theatre costs (including costs for recovery and excluding per-
sonnel costs for anaesthetists and surgeons) were calculated
according to a rate per hour and a fixed fee per visit.
Intensive care unit costs included costs for all ICU provisions
and costs of personnel, including the intensivist, and were calcu-
lated according to the actual time used. A medium-care surgical
ward was defined as a ward with monitoring facilities and a higher
nurse : patient ratio than a standard ward. In this setting, patients
are cared for under the supervision of the surgical team. Only
in-hospital costs were calculated. Extra costs for home nursing,
convalescence or patient-based costs were not included in
this study.
All costs including those quoted from literature were trans-
ferred into US dollars. The (historic) exchange rates as provided
by the Reserve Bank of New Zealand were used.17 For the data
presented in this study, the average exchange rate of September
2010 (NZ$1.00 = US$0.7259) was used. For quoted data, the rate
at the month of publication was used. Correction for inflation or
devaluation was not performed.
Statistical analysis was performed using StatView® 5.0.1 (SAS
Institute, Inc., Cary, NC, USA). Statistical differences were com-
puted using the Mann–Whitney U-test for continuous data and
the chi-squared and Fisher’s exact tests for categorized data. A
P-value of <0.05 was considered significant.
Medical ethical approval was obtained from the Upper South A
Regional Ethical Committee, Ministry of Health, New Zealand.
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Results
Between 22 October 2005 and 31 December 2008, a total of 577
patients were admitted or referred to our institution with acute
pancreatitis. Of these, 260 (45.1%) patients were predicted to have
severe pancreatitis according to either an APACHE II (Acute
Physiology and Chronic Health Evaluation) score 8 (30.0%) or
a C-reactive protein (CRP) level 150 mg/l (37.2%). Twenty-five
(4.3%) patients underwent a pancreatic necrosectomy and all
others were managed non-operatively. Patient demographics and
severity of illness are shown in Table 1. The rate of existing
co-morbidity was low and referred to hypertension, mild asthma
and atrial fibrillation in four patients equally divided over both
groups and one case of obesity in the open-surgery group. The
other patients had no relevant medical history.
In the 25 patients who underwent pancreatic necrosectomy,
pancreatitis was caused by cholelithiasis (n = 18), was idiopathic
(n = 3), reflected pancreatic divisum (n = 1), occurred post-
endoscopic retrograde cholangiopancreatography (ERCP) (n = 1),
was caused by alcohol abuse (n = 1) and was familial (n = 1). The
indication for necrosectomy was proven infection in 13 patients
(nine had evidence of extraluminal gas on CT, four had positive
FNA), persistent SIRS despite maximal conservative treatment in
11 patients and haemorrhage into the necrosis which was not
controlled by interventional radiology in one patient.
Thirteen patients were treated with MIRP. An open approach
was chosen in the remaining 12 patients because the necrosis was
not reachable by MIRP (n = 6), co-existing bowel ischaemia of the
transverse colon was shown on preoperative CT (n = 2), haemor-
rhage into necrosis occurred (n = 1), large intra-abdominal col-
lections not amenable to percutaneous drainage were found (n =
1), the MIRP instruments were too short to reach the necrotic
cavity in an obese patient (n = 1), and the surgeon was unskilled in
MIRP (n = 1). The median time to surgery was significantly longer
in the MIRP group compared with the open-surgery group, at 25
days (range: 8–44 days) vs. 13 days (range: 1–92 days), respectively
(P = 0.032). Two of the 25 patients died while in hospital; one of
these deaths occurred in each group (P = 1.00).
Costs of treatment are shown in Table 2. The median total cost
was US$56 674 (range: US$11 259–223 177). There was no sig-
nificant difference in cost between open necrosectomy (median
cost: US$60 913; range: US$11 259–138 802) and MIRP (median
cost: US$56 673; range: US$23 317–223 177) (P = 0.786). The
median largest contributor to overall costs was represented by
ward costs (26.3%), followed by surgery personnel costs (22.3%)
and ICU costs (17.0%). Neither the actual costs nor the propor-
tion of costs differed significantly between the groups. The only
significant differences were seen in personnel costs for anaesthesia
(P = 0.022), theatre costs (P = 0.009), which reflected the larger
number of theatre visits for MIRP procedures, and pathology
costs (P = 0.002), which mainly reflected the number of bowel
resections conducted in the open-surgery group. None of these,
however, represented a major contribution to the total costs.
At a rate of US$2864/bed/day, the costs of ICU care consumed
a median of 29.9% (range: 0.0–72.2%) of overall costs in the
open-surgery group and a median of 4.0% (range: 0.0–87.2%) of
overall costs in the MIRP group for median stays of 5.0 days
(range: 0.0–34.0 days) and 0.8 days (range: 0.0–61.6 days), respec-
tively (Table 2). Although the MIRP group had a lower median
need for ICU, it included the three most expensive patients, who
remained in the ICU longest (Fig. 1). A more detailed breakdown
of ICU need and length of stay by treatment type is shown in
Table 3. No difference in preoperative, postoperative or total ICU
stay between the two groups (open surgery vs. MIRP) was noted.
The most costly patient remained in the ICU for 61.6 days, which
accounted for US$176 511 (79.1%) of a total treatment cost of
US$223 177.
Discussion
As the understanding of the pathophysiology of pancreatitis has
increased, indications for intervention have changed. Since it
emerged that delaying surgery for pancreatitis leads to a survival
benefit,10 it has become recognized that the disease ‘acts’ in two
stages.3,18 The first phase concerns a sterile SIRS response to the
decay of pancreatic tissue, which is followed by an infection of the
Table 1 Demographics and severity of illness in the 25 patients who underwent pancreatic necrosectomy between October 2005 and
December 2008
Variable Total Open surgery MIRP P-value
Patients, n 25 12 13
Median (range) age, years 55 (20–81) 55 (20–77) 53.5 (21–81) 0.892
Male, n 15 8 7 0.688
Tertiary referral, n 19 10 9 0.645
Median (range) APACHE II score 9.0 (3–17) 7.5 (3–16) 9.0 (5–17) 0.525
Median (range) CRP 320 (124–446) 295 (124–421) 345 (226–446) 0.204
Necrosis >50%, n 16 6 10 0.226
Infected necrosis, n 17 9 8 0.670
MIRP, minimally invasive retroperitoneal pancreatic necrosectomy; CRP, c-reactive protein
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Figure 1 Breakdown of hospital costs by treatment modality per patient ranked by total costs; the same scale is used for both groups.
(A) Open necrosectomy patients. (B) Minimally invasive necrosectomy patients
Table 3 Comparison of specified intensive care unit (ICU) use between treatment modalities
ICU need Open surgery (n = 12) MIRP (n = 13) P-value
Median (range) time to surgery, days 13 (1–92) 25 (8–44) 0.032
Preoperative ICU need, n 3/12 4/13 0.471
Median (range) preoperative ICU stay if needed, days 6.0 (1–7) 4.0 (1–18) 0.361
Postoperative ICU need, n 9/12 6/13 0.141
Median (range) postoperative ICU stay if needed, days 6.0 (1–33) 13.0 (1–58) 0.773
Overall ICU need, n 9/12 8/13 0.471
Median (range) overall ICU stay if needed, days 6.0 (1–34) 5.5 (1–62) 0.597
MIRP, minimally invasive retroperitoneal pancreatic necrosectomy
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necrotic pancreatic tissue in 40–70% of patients.3,18,19 This leads to
a second episode of sepsis. The probability of secondary infection
increases with the amount of necrosis3,19 and previously estab-
lished bacteraemia.19 Secondary infection occurs during weeks
2–7 and peaks in incidence during weeks 3–4.3,18–20 It is now gen-
erally agreed that medical support represents the treatment of
choice in the first phase of the disease and surgical intervention is
kept for the second phase.3,18 A recent review showed that post-
poned surgery was associated with lower mortality rates and most
centres delayed surgical intervention for a median of 26 days.11
However, most patients admitted for pancreatitis will have mild
and self-limiting disease; only 10–20% need ICU treatment1,3,21
and fewer will develop secondary infection. The current series
confirms this: 260 (45.1%) of our 577 patients were predicted to
have severe pancreatitis according to the UK Guidelines,2 but only
25 (4.3%) patients eventually required surgical intervention. Both
the APACHE II score and the CRP are considered to overestimate
the incidence of actual severe pancreatitis.22,23
Two previous cost analyses in patients undergoing pancreatic
necrosectomy were identified. Fenton-Lee and Imrie performed a
cost analysis in 1992 on 10 patients treated with open necrosec-
tomy and related the outcome to a quality of life scale resulting in
a cost of US$3214/life-year saved for an average of 8.5 years
saved.24 However, the calculations assumed a 100% mortality rate
in the absence of surgery and a life expectancy of 75 years. These
assumptions were justly challenged because four of the 10 patients
did not have infected necrosis and one was a 29-year-old alcoholic
for whom a life expectancy of 75 years might prove something of
a challenge.25
The other cost analysis was conducted as part of the PANTER
trial.5 Although this trial found a significant reduction in new ICU
admissions after first treatment in favour of the step-up approach,
it failed to find any significant reduction in overall ICU use or
hospital stay.5 It may well be that longer stays in the ICU before
first treatment in the step-up approach group counteracted the
advantage conferred by the lower number of new admissions
afterwards. In the current series, patients in the open-surgery
group were operated on significantly earlier. The PANTER trial
used the same timescale for the first intervention of drainage vs.
open surgery. In its drainage group, 60% of subjects ultimately
required further (minimally invasive) surgical intervention, which
was performed at a median of 10 days (range: 1–52 days) later.5
The current series did not show a difference in costs between
surgical approaches, despite the increased number of complex
patients in the open-surgery group (ischaemic colon, large intra-
abdominal collection, active bleeding). However, there exists a
significant risk for type II error. Although the PANTER trial
showed a cost benefit of US$14 558 (95% confidence interval [CI]
-32 071 to 61 188) in favour of the step-up approach,5 only
US$6533 of this was saved on in-hospital costs. The other main
savings referred to nursing home costs US$2318 (95% CI -2218 to
6349) and the costs of absence from work during the 6 months
follow-up US$3690 (95% CI -2722 to 9321). Ward and ICU costs
accounted for 33.7–37.2% and 45.2–48.1% of in-hospital costs,
respectively. Both had a huge 95% CI ranging into both negative
and positive values and indicating that there was no significant
difference between the two groups. All the other costs accounted
for 18% of the total in-hospital costs.
The large spread in both series of ICU use, hospital stay and
equivalent treatment costs, of which 65%24 to 82%5 was spent on
ward costs including ICU costs, is mirrored in the current study.
Other non-cost studies have shown the same huge spread in
lengths of ICU and hospital stay.18,20 Although the current study
found the median ICU stay in the MIRP group to be shorter,
this group also contained the three patients who remained longest
in the ICU and therefore the difference in costs between the
open-surgery and MIRP groups was not statistically significant
(P = 0.532).
The various studies cite average daily costs of an ICU bed in
the range of US$1047–4000, according to the country of study
and the time of research.18,26,27 New Zealand’s rate of US$2864 lies
in the middle of that range. The lowest estimate, of US$1047, is
cited by Moerer et al., of Germany, in whose study the most
expensive patient group included patients who underwent acute
surgery, were maintained on ventilating machines and were septic,
which increased the cost of an ICU bed to US$1947 407.27 All of
these conditions apply to patients with infected necrotizing pan-
creatitis. Given the high daily cost of ICU care, it is highly likely
that any measure that can shorten the first episode or prevent the
second episode of sepsis and therefore reduce the ICU stay will be
cost-effective. However, neither probiotics,28 antibiotics,29,30 early
ERCP31,32 or (par)enteral feeding33 has yet made a significant con-
tribution to improving the outcome of necrotizing pancreatitis.
Finally, the costs of longterm complications in this study were
not included. The overall costs of treatment of pancreatitis are
further increased by the fact that over 60% of survivors can be
expected to develop longterm complications: 16% are likely to
need a re-operation;4 7–33% will develop exocrine insufficiency,
and 16–38% will become endocrine-insufficient.4,8
Conclusions
It is clear from this study that the major costs associated with
treating necrotizing pancreatitis are ward, surgical personnel and
ICU costs. However, there is significant variation amongst indi-
vidual patients, reflecting the heterogeneity of this patient group.
The current study did not demonstrate a difference in costs
between the open-surgery and minimally invasive treatment
modalities, although the small sample size may have precluded the
detection of a true difference. Any measure that can reduce hos-
pital and, especially, ICU stay either by shortening the first episode
of sepsis or by preventing secondary infection will, in addition to
improving the quality of patient care, very likely be cost-effective.
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